A NGIOGENESIS, THE FORMATION of new blood vessels, is essential for tumor growth, expansion, and metastasis (1, 2) . Clinical studies have suggested that targeting angiogenesis is a useful approach for controlling the growth of breast tumors (3) (4) (5) (6) (7) . Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic growth factors, and its effects on the proliferation, survival, and permeability of endothelial cells have been extensively studied (8, 9) . VEGF165 and VEGF121 are the predominant isoforms detected in most tissues (8) . Whereas both VEGF165 and VEGF121 are released from normal and tumor cells to initiate angiogenesis, VEGF189 remains bound to the cell matrix (8) . Angiogenesis is a complex process that is regulated by both activators and inhibitors (10, 11) . It has recently been shown that an angiogenic switch is triggered when the level of activators exceeds that of inhibitors, allowing angiogenesis and subsequent tumor growth to proceed (10, 12) . VEGF regulates the angiogenic switch by elevating the angiogenic potential of tissues. Although the precise signals that increase VEGF levels and/or allow tumor cells to acquire the angiogenic switch have not been completely delineated, hypoxia, oncogenes, pH, and steroid hormones are examples of stimuli that are known to induce VEGF expression in tumor cells (13, 14) .
Breast cancer is the second most common cause of cancer death in women in the United States. Considerable interest has focused on the possibility of inhibiting VEGF to prevent or control the growth of breast cancer (15) (16) (17) (18) (19) . For this reason, the role of VEGF and angiogenesis in breast cancer has been extensively studied (7, 19) . The proliferation of many breast cancer cells is controlled by the sex steroids estrogens and progesterone. Although the effects of these hormones on the proliferation of breast cancer cells has been well studied (20) , little attention has been paid to the role of sex-steroid hormones and their receptors in controlling the process of angiogenesis for nourishment of tumor tissue (14, 21) .
Recent evidence has indicated that there is an increased risk of breast cancer in women that consume a combined regimen of estrogen and progestin for hormone replacement therapy (HRT), as compared with those that take estrogen alone or a placebo (22, 23) . This has renewed interest in the role of synthetic progestins in tumor growth. We previously reported that both natural and synthetic progestins used in oral contraceptives or HRT induce VEGF secretion in T47-D and BT-474 breast cancer cells through the progesterone receptor (PR), mainly the progesterone receptor B (PRB) isoform (24) (25) (26) . The hormone-induced expression of VEGF is PR dependent (27) and occurs primarily in cells that lack the p53 tumor suppressor protein (26) . Inhibition of VEGF has been shown to reduce the growth of breast tumors in animal models, as well as the proliferation of breast cancer cells in vitro (17, (28) (29) (30) (31) . Thus, it may be possible to control the growth of breast cancer in humans by blocking the effects of VEGF in vivo.
We have demonstrated that the natural hormone progesterone as well as the synthetic progestin medroxyprogesterone acetate (MPA), which is extensively used for HRT, regulate VEGF in a subset of breast cancer cells (24) (25) (26) . However, it is not known whether these progestins induce VEGF expression in tumor cells through common or distinct pathways. The present study was designed to delineate the intracellular signaling pathways involved in this process. Identification of the specific pathways involved may provide a critical first step toward developing therapies to control the effects of progestins on VEGF-mediated angiogenesis.
We performed experiments designed to determine whether progesterone and MPA utilize similar signaling pathways to induce PR-dependent expression of VEGF in T47-D CO and BT-474 cells. We evaluated the phosphoinositide-3Ј-kinase (PI3-kinase) signaling pathway, the MAPK signaling pathways, and a pathway that regulates the transcription factor specificity protein-1 (SP-1), which is known to be involved in VEGF synthesis and release (32, 33) . We report that progestin-induced regulation of VEGF in breast cancer cells is predominantly controlled by the PI3-kinase pathway and the SP-1 transcription factor. In addition, the induction of VEGF in response to the natural and synthetic ligand is differentially sensitive to inhibition of the MAPK kinases (MEK1/2) and the N-terminal jun kinase (JNK) MAPK signaling pathways in a cell-dependent manner. Furthermore, we report the novel observation that the MAPK signaling pathways regulate progesterone-dependent VEGF synthesis and secretion at the posttranscriptional level in a subset of breast cancer cells.
RESULTS

Inhibitors of Various Signal Transduction Pathways Regulate Progestin-Induced VEGF Secretion in a Ligand-and Cell Type-Dependent Manner in Breast Cancer Cells
We investigated the role of the PI3-kinase, MEK1/2/ ERK/MAPK-, and JNK/MAPK signaling pathways and the SP-1 transcription factor on progestin-induced expression of VEGF in two different breast cancer cell lines, T47-D CO and BT-474 cells. These cells lines contain tumor suppressor p53 with mutations within the DNA binding domain of the protein (26, 34) . Most other breast cancer cell lines containing wild-type p53 do not respond to progestin by increasing VEGF levels (24, 26) . The inhibitors used included LY294002 (a specific inhibitor of PI3-kinase), U0126 (a specific inhibitor of MEK1/2), SP600125 (a specific inhibitor of JNK), and mithramycin, which inhibits the transcriptional activity of SP-1 (35) (36) (37) . Figure 1A shows that both progesterone and MPA increase VEGF levels in BT-474 cells. All four of the inhibitors tested, LY294002, U0126, SP600125, and mithramycin, blocked both the progesterone-and MPA-induced increases in VEGF secretion in the BT-474 breast cancer cells. The inhibitors themselves (in the absence of progesterone and MPA) also decreased basal levels of VEGF production in these cells, with the SP-1 inhibitor mithramycin having the greatest effect on basal VEGF levels.
We next evaluated the role of these signal transduction pathways on progestin-induced VEGF expression in T47-D CO cells. In contrast to the effects observed in BT-474 cells, the various inhibitors had differential effects on VEGF secretion in T47-D CO cells (Fig. 1B) . All of the inhibitors blocked the effects of progesterone on VEGF secretion from the T47-D CO cells. However, only the PI3-kinase inhibitor (LY294002) and the SP-1 inhibitor (mithramycin) blocked MPA-induced VEGF secretion in this cell type (Fig. 1B) . The MEK1/2 and JNK inhibitors had no effect on MPA-induced VEGF levels. SB203580, which specifically inhibits the phosphorylation and activation of the p38 MAPK, also had no effect on MPA-induced VEGF secretion (data not shown). These MAPK inhibitors also failed to block VEGF secretion when T47-D CO cells were stimulated with norgestrel, another synthetic progestin (data not shown). Both LY294002 and mithramycin also inhibited basal levels of VEGF secretion from the T47-D CO cells (Fig. 1B) . These results suggest that signaling through the PI3-kinase and SP-1 pathways directly regulate secretion of VEGF from BT-474 and T47-D CO cells (Fig. 1, A and B) .
To determine whether the inhibitors used in this study influenced PR levels, we incubated T47-D CO and BT-474 cells for 18 h in the presence or absence of these inhibitors and determined PR levels by subjecting whole cell extracts to Western blot analysis. As shown in Fig. 1C , although there was some variation in the overall levels of PR, PR levels remained stable during treatment with the various inhibitors tested in either cell line within the time frame used for these experiments.
The PRA and PRB Isoforms Differentially Inhibit Ligand-Dependent VEGF Secretion in Response to Inhibition of MEK1/2
We have previously shown that PRB appears to be the dominant receptor that controls VEGF synthesis and secretion in the T47-D CO cells (25) . Because the MAPK inhibitors differentially inhibited progesterone-and MPA-induced increases in VEGF secretion in T47-D CO cells, we investigated whether this effect was specific for the individual PR isoforms. To do this, we used two different T47-D CO -derived breast cancer cell lines that were engineered to express equal levels of either only PRA (YA) or only PRB (YB) (38) . These cell lines have also been shown to retain other (PR independent) signaling pathways that control VEGF secretion (25) .
YB and YA cells were pretreated with LY294002, U0126, SP600125, or mithramycin before being exposed to progesterone, and the resulting VEGF levels were determined. As in the parental T47-D CO cells, LY294002 blocked progestin-dependent VEGF secretion from both YB and YA cells, indicating that the PI3-kinase pathway predominantly controls progestin-dependent induction of VEGF in T47-D CO breast cancer cells (Fig. 2, A and B) . LY294002 also inhibited basal levels of VEGF secretion from both YA and YB cells. Thus, inhibition of the PI3-kinase signaling pathway blocked the progestindependent induction of VEGF irrespective of the ligand or receptor subtype present. In YB cells, the MEK1/2 inhibitor U0126 blocked progesteronedependent VEGF secretion, but not MPA-dependent VEGF secretion ( Fig. 2A) . In YA cells, however, U0126 blocked the VEGF secretion induced by both progestin ligands (Fig. 2B ). U0126 also blocked the basal level of VEGF secretion from the YA cells. In contrast, the JNK inhibitor SP600125 only partially blocked progesterone-induced VEGF secretion from YB and YA cells, and it did not inhibit the MPAinduced VEGF secretion from either cell type (Fig. 2,  A and B) . Similar results were obtained when the effects of these inhibitors were tested on norgestrel, another synthetic progestin (data not shown). It is important to note that the insensitivity of MPAinduced VEGF secretion to the MEK1/2 inhibitor U0126 seems specific to YB cells obtained initially from the T47-D CO cell type (38) , as U0126 still abrogated MPA-dependent induction of VEGF in BT-474 cells, even when these cells were transiently transfected with a PRB expression vector (data not shown). Mithramycin, which inhibits the actions of the SP-1 transcription factors, completely abrogated progesterone-or MPA-induced VEGF induction in both YB and the YA cells (Fig. 2, A and B) . (within 2 min). However, p-AKT levels then decreased at 10 min and once again became phosphorylated at 40 and 120 min (Fig. 3A) . Similar results were obtained when BT-474 cells were stimulated with the synthetic progestin MPA (Fig. 3B ). As shown in Fig. 3C , progesteroneand MPA-induced activation of ERK was blocked by both U0126 and by the progesterone antagonist RU-486. The effect of RU-486 indicates that the phosphorylation of ERK induced by progesterone and MPA is PR dependent. As shown in Fig. 3D , LY294002 blocked both progesterone-and MPA-induced phosphorylation of AKT in BT-474 cells.
We next evaluated the role of the ERK and PI3-kinase signaling pathways in the effects of progesterone and MPA on T47-D CO cells. As shown in Fig. 4A , progesterone rapidly but transiently induced phosphorylation of ERK. The maximal response was observed between 5 and 10 min after progesterone treatment and p-ERK levels diminished between 40 min and 120 min. Unlike progesterone, MPA did not induce any significant increase in phospho-ERK levels ( Fig.  4B ). However, p-ERK levels decreased below basal levels 40 and 120 min after exposure to MPA, similar to what was observed with progesterone. There were no changes in the total amount of ERK in response to either progesterone or MPA treatment.
We also examined the effects of progesterone and MPA on AKT, a downstream target of PI3-kinase. In contrast to the differential effects of progesterone and MPA on phosphorylation of ERK in T47-D CO cells, 40 min of exposure to either progesterone or MPAinduced phosphorylation of AKT at serine 473, but not at threonine 308 (Fig. 4, A and B) . Progesteroneinduced phosphorylation of ERK was completely blocked by both U0126 and RU-486 in T47-D CO cells (Fig. 4C) . Each of these inhibitors also decreased basal levels of ERK phosphorylation. The effects of RU-486 suggest that progesterone-induced phosphorylation of ERK is PR-dependent and that the unliganded PR may play a role in maintaining basal levels of ERK activation. The PI3-kinase inhibitor LY294002 completely blocked progesterone-or MPA-induced phosphorylation of phospho-AKT at Ser473 (Fig. 4C) .
Because the progestin-dependent induction of VEGF is primarily controlled by PRB (25), we next evaluated the roles of the ERK and PI3-kinase signaling pathways on the effects of these progestins in YB cells. As shown in Fig. 5, A and B, the effects of progesterone and MPA on ERK and AKT in YB cells was similar to that observed in the parental cells (Fig.  4, A and B) . Progesterone rapidly stimulated the phosphorylation of ERK in YB cells (Fig. 5A ), but MPA did not (Fig. 5B) . However, both progesterone and MPAinduced phosphorylation of AKT at serine 473, indicating that the PI3-kinase signaling pathway was activated by both natural and synthetic progestin ligands (Fig. 5, A and B) .
As in T47-D CO cells, progesterone-induced phosphorylation of ERK was completely blocked by U0126 in YB cells (Fig. 5C ). However, RU-486 only partially blocked progesterone-induced phosphorylation of ERK in YB cells (Fig. 5C ), unlike its effects in T47-D CO cells (Fig. 4C) . The inability of RU-486 to completely block progesterone-induced ERK activation may explain the partial agonist effects of antihormones observed in the PRB cell line (43) (44) (45) , as well as why RU-486 is a weak agonist for inducing transcriptional activity via a progesterone re- Ϫ6 M RU486 (RU), followed by treatment with 10 Ϫ8 M progesterone (P) or 10 Ϫ8 M MPA, as indicated. Whole cell lysates were then subjected to Western blot analysis for phospho-ERK, total ERK, phospho-AKT (Ser 473), and total AKT, as shown.
sponse element linked to a luciferase reporter plasmid (PRE-luc) in YB cells (43, 44) .
To further characterize the roles of PI3-kinase and ERK in VEGF secretion, we treated T47-D CO and YB cells with the PI3-kinase inhibitor LY294002 before stimulation with progesterone. The effects of progesterone on the phosphorylation of AKT and ERK were then determined. As shown in Fig. 6 , the PI3-kinase inhibitor LY294002 blocked progesterone-induced phosphorylation of ERK in both T47-D CO and in YB cells. As shown previously in Figs. 4C and 5C, LY294002 also blocks the phosphorylation of AKT in both T47-D CO and in YB cells. Thus, the findings presented in Fig. 6 suggest that, like AKT, ERK is a downstream target for PI3-kinase mediated signaling events in T47-D CO cells.
Progesterone and MPA Regulate the Phosphorylation of Cytosolic and Nuclear ERK in Breast Cancer Cells
The findings presented above indicate that progesterone and MPA have both similar and divergent effects on the MAPK activation in the BT-474 and T47-D CO cells (Figs. 1-6 ). Both ligands increased p-ERK levels in the whole cell extracts from BT-474 cells, but only progesterone increased p-ERK in T47-D CO cells. These results suggested that the point of convergence of these two hormones in T47-D CO cells is most likely at the level of MAPK activation because MPA fails to activate MAPK. However, other studies have shown that progesterone and MPA may differentially induce nuclear translocation of p-ERK in neuronal cells (46) . To rule out this possibility as an explanation for the observed effects between progesterone and MPA in T47-D CO cells, we determined the effects of hormone exposure on p-ERK levels in cytosolic and nuclear extracts. As shown in Fig. 7 , progesterone and MPAregulated p-ERK levels in cytosolic and nuclear extracts in a pattern similar to what was observed in whole cell extracts (Figs. 3 and 4) . In BT-474 cells, both progesterone and MPA rapidly increased p-ERK in cytosolic and nuclear extracts (within 2 min), indicating that p-ERK was rapidly translocated to the nucleus (Fig. 7) . In T47-D CO cells, progesterone treatment led to increased p-ERK within 2-5 min in both nuclear and cytosolic extracts; however, MPA did not increase p-ERK levels in either the cytosolic or nuclear fraction. In fact, MPA actually decreased p-ERK levels to below basal levels in both the cytosolic and nuclear fractions of T47-D CO cells, similar to what was observed in whole cell extracts (Fig. 4) . These results indicate that the differential response of progesterone and MPA in the T47-D CO cells occurs at the level of activation of the MAPK pathway and is not dependent on the nuclear translocation of p-ERK.
Influence of Signal Transduction Pathway Inhibitors on Progestin-Dependent Transcription of the Endogenous VEGF Gene
Because various inhibitors of specific signal transduction pathways differentially blocked progestininduced VEGF secretion from T47-D CO cells, we next used real-time PCR to determine whether these inhibitors also differentially influenced expression of the VEGF gene. T47-D CO cells were treated with either LY294002 or U0126 for 30 min before a 6-h exposure to progesterone or MPA. The relative levels of VEGF mRNA were then determined by realtime PCR. As shown in Fig. 8 , RU-486, LY294002, and mithramycin completely blocked progestindependent VEGF expression. However, neither U0126 and nor SB203580 blocked the progesterone or MPAdependent increase in VEGF mRNA levels. This was an unexpected result because these MAPK inhibitors blocked the progesterone-dependent secretion of VEGF from T47-D CO cells under the same conditions.
The Proximal SP-1 Recognition Sites Are Important for Progestin-Dependent Induction of the VEGF Promoter
The proximal SP-1 sites within the VEGF promoter have been shown to influence VEGF induction in response to many different signal transduction pathways, including their involvement in the induction of VEGF by estrogens (47) (48) (49) . We considered the possibility that the proximal SP-1 sites may also be critically involved in the PR-induced expression of VEGF. As shown in Fig. 9A , both the full-length promoter (Ϫ2362/ϩ956) and the truncated reporter plasmid (Ϫ135/ϩ956), containing the four proximal SP-1 sites, were responsive to progesterone, similar to what has been reported previously in endometrial cells (50) . However, progestin-dependent induction of VEGF was blocked when the SP-1 sites in the Ϫ135/ϩ956 construct were either deleted (SacII construct, Fig. 9A ) or when mithramycin was used to block SP-1 activity before the addition of progesterone (Fig. 9A) . Furthermore, when all four SP-1 sites in the Ϫ135/ϩ956 construct were mutated to prevent binding of the transcription factor to this region, progesterone failed to induce luciferase activity (Fig. 9B) . These data suggest that the region within the VEGF promoter that includes the proximal SP-1 sites is critical for mediating progestin-dependent induction of VEGF in breast cancer cells.
Inhibitors of the PI3-Kinase, MEK1/2, and JNK Signaling Pathways, and the SP-1 Transcription Factor, Do Not Inhibit PRE-Dependent Gene Expression in Response to Natural or Synthetic Progestins
Because LY294002 and mithramycin blocked the progesterone-or MPA-induced increases in VEGF mRNA levels in T47-D CO cells, we next asked whether these inhibitors had any effect on the ability of PR to induce PRE-dependent gene expression. T47-D CO and YB
Fig. 9. Progestin Induction of VEGF Promoter in the Presence and Absence of SP-1 Binding Sites
A, Full-length and truncated constructs of the VEGF promoter were transfected into the T47-Dco cells that were kept overnight in DMEM/F12 ϩ 5% dextran-coated charcoal-stripped serum. Cells were then treated with mithramycin for 2 h, followed by incubation with 10 nM progesterone or 1 M RU-486 for 18 h. E, Four proximal Sp-1 sites. B, The four proximal SP-1 sites were mutated as shown in the upper panel. The wild-type and mutated constructs were transfected into T47-Dco cells and incubated for an additional 18 h in the presence of progesterone and/or RU-486. In the lower panel, represent the mutated SP-1 sites. Asterisks represent induction values that are significantly different from controls (P Ͻ 0.05; two-tailed Student's t test). cells were transfected with the PRE-Luc reporter construct as described in Materials and Methods. The cells were pretreated for 30 min with the various inhibitors at the indicated concentrations, followed by treatment with either progesterone or MPA for 18 h. As shown in Fig. 10, A and B , none of the inhibitors that were tested completely blocked progestin-induced activation of the PRE-Luc construct. However, the SP-1 inhibitor consistently reduced progestin-induced activation of PRE-Luc. However, the MEK1/2 inhibitor consistently increased PRE-Luc activity in T47-D co cells, but not in YB cells. Thus, the inhibition of progestin-induced expression of VEGF mRNA and VEGF secretion observed in response to inhibition of the PI3-kinase and SP-1 signaling pathways does not appear to be caused by direct effects of these signaling pathways on the PR protein or PR function.
DISCUSSION
We have previously shown that both natural and synthetic progestins increase VEGF expression and secretion from human breast cancer cells in a PRdependent manner, and that this is mainly controlled by the PRB isoform (24) (25) (26) (27) . PRB also appears to be a dominant regulator of gene expression for other progestin-responsive genes in endometrial cells (51) . Synthetic progestins, particularly MPA, are commonly prescribed in therapy regimens to negate the untoward effects of estrogens on the uterus. The use of MPA by millions of women all over the world is associated with increased risk of breast cancer (22, 23) . Because VEGF is a target for controlling the angiogenic switch as well as expansion and spread of tumors (10, 11), we investigated the signal transduction pathways used by progesterone and MPA that control VEGF production in T47-D CO and BT-474 breast cancer cells.
Our findings show that both natural and synthetic progestins induce VEGF expression and secretion primarily through the PI3-kinase signaling pathway and the SP-1 transcription factor. Furthermore, the proximal SP-1 binding sites on the VEGF promoter were critical for progestin-mediated VEGF induction. These proximal binding sites for SP-1 transcription factor have also been shown to play a role in mediating VEGF induction through various signal transduction pathways, including estrogen-dependent induction of VEGF (47) (48) (49) . In BT-474 cells, both natural and synthetic progestins utilize the ERK and JNK MAPK signaling pathways in VEGF induction. However, only the natural hormone used these pathways in T47-D CO cells because MAPK inhibitors had no effect on MPAor norgestrel-induced VEGF levels in these cells. This suggests that utilization of the MAPK signaling pathway by synthetic progestins occurs in a cell-and ligand-type-specific manner. To our knowledge, this is the first time that a potent angiogenic factor has been shown to be differentially controlled by synthetic progestins in different breast cancer cell types. The findings also suggest that MAPK inhibitors may not be suitable for effectively controlling progestin-dependent production of VEGF from certain breast cancer cells. Several previous reports have identified differences in regulation of natural vs. synthetic progestins, including differences in their ability to cause tumor cell proliferation (46, (52) (53) (54) (55) . Other reports have also shown that natural and synthetic progestins differentially target the PI3-kinase and MAPK signaling pathways (42) . The molecular basis for these differences between natural and synthetic progestins is uncertain. However, it is possible that differential metabolism of these progestins in various breast cancer cells may yield metabolites that do not effect the MAPK signaling pathway for increasing VEGF production from certain breast cancer cells. Further studies will be needed to evaluate the role of various progestin metabolites on VEGF induction in tumors.
In normal breast tissue, the ratio of PRA to PRB is close to one; however, this ratio can vary considerably in breast tumors (56) (57) (58) . PRA and PRB differentially regulate progestin-responsive genes (25, 59, 60) , and selective modulation of these receptor isoforms lead to characteristic reproductive abnormalities (61, 62) . To determine whether the specific PR isoforms could differentially influence the activity of natural and synthetic progestins, we used T47-D CO -derived cells that express only PRA or PRB (38) . We found that the MEK1/2 inhibitor U0126 blocked both progesteroneand MPA-induced secretion of VEGF in T47-D CO cells expressing only the PRA isoform. However, U0126 blocked progesterone, but not MPA-induced secretion of VEGF in cells that expressed only PRB. It is possible that in cells expressing only PRB, induction of a PRB-specific gene may lead to the metabolism of the synthetic progestin and thereby allow an alternative pathway to induce VEGF expression. A similar effect has been documented by Horwitz et al. and is believed to promote carcinogenicity with tamoxifen in a receptor-dependent manner (63) . Further study will be necessary to understand why MPA-induced VEGF expression is independent of the ERK signaling pathway in YB cells. When PRB was overexpressed in BT-474 cells by transient transfection, progesteroneand MPA-induced VEGF expression remained sensitive to the MEK1/2 inhibitor U0126 (Fig. 1A and data  not shown) . Thus, the inability of U0126 to prevent MPA-induced VEGF production in YB cells seems to be cell type dependent. However, it is possible that transient transfections did not lead to PRB expression levels comparable to what are found in the T47-D CO cells. Also, unlike YB cells, the BT-474 cells transiently transfected with PRB also express PRA, and this may override any PRB-dependent effects that allow the ERK/MAPK pathway to be bypassed in BT-474 cells. It will be useful to isolate BT-474 clones that lack the PR, as has been done for T47-D CO cells (38) . The individual PRA and PRB isoforms can then be reintroduced into the modified BT-474 cells to reach the levels similar to those present in the T47D CO cells. One could then determine whether high levels of PRB lead to MPA-dependent VEGF induction that is independent of the MAPK pathway. It is also important to note that although MPA-induced VEGF secretion could be blocked by inhibitors of MEK1/2/MAPK in the absence of PRB, MPA-induced VEGF secretion remained independent of the JNK/MAPK signaling pathway in YB, YA, and parental T47-D CO cells. Thus, MPA uses a pathway that is distinct from the one used by the natural hormone progesterone to mediate VEGF induction in T47-D CO cells. Interestingly, the JNK/MAPK signaling pathway is involved in VEGF induction in BT-474 cells because inhibition of JNK/MAPK blocked both progesterone-and MPA-induced VEGF expression in this cell type. Such heterogeneity among cells within a tumor may limit the effectiveness of drugs that target only the ERK signaling pathway to reduce progestin-mediated VEGF induction because there may be a continuous supply of an angiogenic growth factor under these conditions. The ability of progesterone or MPA to regulate VEGF in BT-474 and T47-D CO cells was correlated with the ability of the ligand to induce activation of the PI3-kinase or the ERK signaling pathways. In BT-474 cells, both the PI3-kinase and the ERK signaling pathways were activated by progesterone and MPA treatment and this correlated with the ability of inhibitors of these pathways to block progesterone-or MPA-induced VEGF expression. However, the natural and synthetic progestins did not exert the same effects in T47-D CO and YB cells. As in BT-474 cells, progesterone activated both the ERK and the PI3-kinase pathways in T47-D CO and YB cells. However, MPA activated only the PI3-kinase pathway in T47-D CO and YB cells. Similar effects were observed in response to norgestrel, another synthetic ligand (data not shown), indicating that the structure of the natural ligand is important for initiating the effects of MAPK. Clearly, more extensive studies with various progestins will be required to better understand the role of ligand structure and metabolism and how these factors may control various signal transduction pathways in breast cancer cells. Nevertheless, it is intriguing that different ligands can regulate VEGF via specific signal transduction pathways in specific cell types. In addition to regulating VEGF, the MAPK signaling pathway is also known to regulate genes or proteins involved in cellular proliferation. In such situations, progestin-dependent VEGF induction would be predicted to lead to increased angiogenesis associated with increased cellular proliferation. This may be related to the finding that the use of synthetic progestins can lead to increased risk of breast cancer (22, 23) .
To our knowledge, this is the first time that different signal transduction pathways have been shown to be used by natural vs. synthetic progestins for the induction of an angiogenic growth factor associated with tumor growth. This may represent the molecular basis for the different pathologies reported in progesteronevs. MPA-induced breast tumors in mice (64, 65) or for the different potencies exhibited by natural and synthetic progestins for inducing proliferation of breast cancer cells in vitro (55, 66) .
When RU-486 was used to block the PR, progestininduced phosphorylation of ERK/MAPK was abolished, indicating that the PR plays a role in this process. This observation also raises the interesting possibility that the PR may possess intrinsic protein kinase activity and phosphorylate the p44/42 proteins directly, although, this remains to be shown. Protein kinase activity has been previously reported to be associated with the PR (67). It is also known that the PR can interact with src and the ER to regulate the MAPK pathway (68) .
The progesterone-induced activation of the ERK/ MAPK pathway was blocked by the PI3-kinase inhibitor LY294002 in T47-D CO cells, indicating that PI3-kinase lies upstream of the ERK/MAPK pathway in these cells and that there is cross talk between these pathways during regulation of VEGF gene expression. However, no such cross talk was observed in the effects of MPA on VEGF. Thus, although the natural hormone utilizes both the PI3-kinase and ERK signaling pathways, the ERK pathway is bypassed by synthetic progestins in certain cells, such as T47-D CO cells. Further investigation will be required to determine whether downstream targets of AKT are shared or distinct in the effects of natural and synthetic progestins on VEGF induction in breast cancer cells.
One of the most interesting findings in this investigation was that inhibition of progestin-mediated increases in VEGF secretion in T47-D CO cells by certain signal transduction inhibitors were not accompanied by loss of expression of the VEGF gene. Although inhibitors of the PI3-kinase signaling pathway and the SP-1 transcription factor abrogated VEGF mRNA expression and secretion from the breast cancer cells, irrespective of the ligand used, the MAPK inhibitors (SB203580 and U0126) blocked progesteroneinduced VEGF secretion from these cells but failed to block increases in VEGF mRNA levels. This indicates a novel role for the MAPK signaling pathways in the posttranscriptional regulation of progesteroneinduced VEGF production. Such regulation may occur at the level of transporting VEGF mRNA from the nucleus into the cytoplasm, at the level of mRNA stability, translation of mRNA into protein, or during the secretion of VEGF from cells. It has been shown that the MAPK signaling pathway is involved in the posttranscriptional control of proteins (69, 70) . Further experiments will clearly be necessary to understand the precise role of MAPK inhibitors on ligand-dependent VEGF secretion in T47-D CO cells.
Interestingly, none of the signal transduction pathway inhibitors that we evaluated dramatically influenced the transcriptional potential of the PR, as determined by analysis of PR-dependent induction of PRE-Luc reporter plasmid. However, we noticed that the MEK1/2 inhibitor consistently increased the induction of PRE-luciferase activity in T47-D CO cells, but not in YB cells. This indicates that perhaps PRB is modifying certain inhibitors. The loss of these inhibitors could lead to the induction of luciferase activity in the presence of U0126. Alternatively, it is possible that coactivators/repressors or receptors are selectively being affected to enhance luciferase activity. It is also possible that in the presence of PRA, T47-D CO cells synthesize certain inhibitors of PRE-luc activity, possibly via the PR. Alternatively, PRA could control the activity of PRB, which leads to enhanced activation of luciferase activity. This suggests that the loss of YA in T47-D co cells selectively allows YB cells to control a cellular component that either activates the PR or potentially stabilizes luciferase mRNA. These results indicate that although the various inhibitors showed slight differences in their abilities to activate PRE-Luc, none of them completely inhibited PRE-Luc, as does the receptor antagonist RU-486. These inhibitors did not alter PR levels in breast cancer cells, but it is possible that they could modify other cofactors associated with the PR. Our findings suggest that when progestin-mediated VEGF production is blocked by the presence of these inhibitors, other posttranscriptional (non-PRE) events must be involved or that other transcription factors (or coactivators/corepressors) are altered and unable to cooperate with the PR at the level of the VEGF gene.
One implication of the current findings is that the induction of VEGF, a potent angiogenic factor, may be involved in the increased risk of breast cancer observed in a subset of women who are prescribed progestins for HRT (22, 23) . The ingestion of progestins may provide the angiogenic switch in preexisting lesions or tumors, and the increased VEGF may facilitate tumor growth. The PI3-kinase pathway and the SP-1 transcription factor appear to play important roles in progestin-mediated VEGF induction in tumor cells. It is important to mention that breast cancer cells could metabolize progestins to compounds that may trigger a growth response (71) (72) (73) , which may also increase VEGF production. The synthetic progestins are less easily metabolized than the natural compound, which has a shorter half-life in tumor cells (71) (72) (73) . Thus, some of the differences we have observed between BT-474 cells and T47-D CO cells with respect to the activation of signal-transduction pathways could result from differential progestin metabolism in these cells. Further studies will be needed to characterize the metabolism of progestins; nevertheless, this does not undermine our observation that breast cancer cells differ in their ability to respond to progestins and differentially activate pathways that could lead to the production of a potent angiogenic factor. Based on our observation that the PI3-kinase signaling pathway and the SP-1 transcription factor appear to be critical for VEGF induction in breast cancer cells, it appears that targeted therapy against PI3-kinase, SP-1, and/or PR may provide an effective antiangiogenic approach to curtail progression of progestin-dependent breast cancer by blocking the secretion of VEGF from breast tumor cells.
In conclusion, our study provides evidence that the PI3-kinase pathway and functional SP-1 protein predominantly control progestin-dependent VEGF induction in response to both the natural hormone progesterone and synthetic ligands in breast cancer cells. In contrast, the utilization of the MAPK pathway for progestin-dependent VEGF induction is ligand and cell type dependent. Thus, blocking the PI3-kinase signaling pathway or the SP-1 transcription factor and/or blocking PR with antiprogestins, could prove effective for suppressing progestin-induced proangiogenic sig-nals that can provide the angiogenic switch for tumor progression.
MATERIALS AND METHODS
Materials
Progesterone (4-pregnene-3,20-dione), medroxy progesterone acetate (MPA; 17␣-hydroxy-6␣-methyl-4-pregnene-3,20-dione17-acetate), RU-486, mithramycin, and LY 294002 were purchased from Sigma (St. Louis, MO). U0126 and SB203580 were purchased from Calbiochem (La Jolla, CA). The inhibitors and concentrations used were chosen based on previous publications (35) (36) (37) , and these concentrations represent values greater than their ED 50 values.
Cell Culture
The PR-positive T47-D CO breast cancer cell line, isolation of T47-D CO -Y, its PR-negative clonal derivative, and construction of PR-positive YA and YB cells have been described previously (38) . All cell lines were grown in phenol red-free DMEM/F12 (Invitrogen Life Technologies, Carlsbad, CA), supplemented with 5% fetal calf serum (FCS, JRH Bioscience, Lanexa, KS). Cells were routinely cultured in 100-mm dishes and incubated at 37 C with 5% CO 2 in a humidified environment. The YA and YB cells were grown in media containing 200 g/ml G418 (Sigma, St. Louis, MO) to select for stable expression of PRA and PRB. BT-474 cells were obtained from ATCC (Manassas, VA). The various inhibitors were added 30 min before the addition of progestin at the indicated concentrations.
VEGF ELISA
VEGF was measured with a Quantikine ELISA kit from R&D Diagnostics (Minneapolis, MN) according to the manufacturer's recommended protocol. VEGF levels were normalized to total cellular protein in each dish using BCA protein assay kit (Pierce, Rockford, IL). Human recombinant VEGF165 was used as a standard and was provided by the manufacturer's of the VEGF ELISA kit. Data were analyzed using a two-tailed Student's t test. P values Ͻ 0.05 were considered to be statistically significant. Inter-and intraassay coefficients of variance were 5.0-8.5% and 3.5-6.5%, respectively, according to the manufacturer.
Plasmids, Transfections, and Luciferase Assays
To construct the luciferase reporter, the PvuII-SmaI fragment was excised from pPRE/GRE.E1b.CAT (26) and ligated into the SmaI site of pGL3Basic (Promega, Madison, WI). pPRE/ GRE.E1b has two copies of the consensus PRE linked to the TATA element from E1b (kindly provided by Dr. Zafar Nawaz, Creighton University, Omaha, NE).
The promoter region of the human VEGF gene (Ϫ2362 to ϩ956 relative to the transcription start site) and various deletion constructs were kindly provided by Dr. Lee Ellis (Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX) (74) . The regulatory sequences were fused to the luciferase reporter gene in pGL3-basic vector (Promega, Madison, WI) to generate pVpecor. The proximal SP-1 sites in the human VEGF gene (ApaI construct, Ϫ135/ϩ956) were mutated by site-directed mutagenesis at Top Gene Technologies (Montreal, Quebec, Canada) with bases that are known to abolish SP-1 binding to the gene (75, 76) . The resulting construct was sequenced and the mutated bases are shown in Fig. 9B . T47-D CO and variant cells were grown in DMEM/F12 supplemented with 10% FCS and plated at 3 ϫ 10 5 /well in Falcon six-well dishes in 5% dextran-coated charcoalstripped serum 24 h before transfection. Cells were transfected with the indicated plasmids using Superfect reagent (QIAGEN, Valencia, CA) according to the manufacturer's guidelines. Cells were washed with PBS and incubated in DMEM/F12 supplemented with 5% FCS in the presence of various hormones, as indicated. Cells were lysed after 20 h, and luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and a Sirius luminometer (Berthold Detection Systems, Pforzheim, Germany). All experiments were performed in triplicate and repeated at least twice. Data were normalized to Renilla luciferase (pRL-CMV plasmid, Promega E2261) activity and expressed as fold increase relative to control levels.
Immunoblotting
Whole cells lysates were prepared in RIPA buffer, as described previously (26) . The cytosolic and nuclear extracts were obtained using NE-PER nuclear and cytoplasmic extraction reagents (Pierce). Equal amounts of protein were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes by electroblotting. After blocking, the membranes were incubated with phosphospecific and nonphosphospecific antibodies directed against p44/p42 MAP-K(Thr 202 /Tyr 204 ), p38 MAPK(Thr 180 /Tyr 182 ), AKT(Ser 473 ) (Cell Signaling, Beverly, MA) and AKT(Thr 308 ) (Upstate, Lake Placid, NY). The secondary antibody was an antirabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), diluted 1:2000 and incubated with the membrane for 1 h. Protein bands were detected using enhanced chemiluminescence plus detection system according to the manufacturer's instructions (Amersham Pharmacia Biotech, Arlington Heights, IL).
Quantitative Real-time PCR
Total RNA was extracted from cells using the Ultraspec RNA Isolation System (Biotex Laboratories, Inc., Houston, TX). RNA was pretreated with deoxyribonuclease I (Invitrogen Life Technologies), and SuperScript (Invitrogen Life Technologies) was used to synthesize cDNA, according to the manufacturer's recommended conditions. The VEGF primers and probe were designed by Lark Technologies, Inc. (Houston, TX). These primers recognize mRNA derived from all VEGF isoforms. Real-time quantitative PCR analysis was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Each sample was analyzed in duplicate with ribosomal 18S RNA was used as an internal control. The sequences of primers and probes used in both assays were proprietary. After amplification, the relative differences in amounts of RNA were calculated based on the 2 Ϫ⌬ ⌬CT method (Applied Biosystems Prism Sequence Detection System User Bulletin #2).
